Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Antengene receives USD60m upfront payment from UCB
Teva and Polpharma Biologics enter global licensing agreement for biosimilar candidate to Ocrevus
United Therapeutics acquires Thymmune Therapeutics to expand regenerative cell therapy pipeline
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
Japan approves Wayrilz for immune thrombocytopenia treatment
Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
Antengene granted IND approval in China for ATG-201 in autoimmune disease
Antengene presents first ATG-207 preclinical data at EULAR 2026
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz